Patents by Inventor Michael Gendreau
Michael Gendreau has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220387042Abstract: The present technology is directed generally to devices, systems, and methods for enclosing anatomical openings. In one example, an aneurysm device is endovascularly deliverable to a site proximate to an arterial aneurysm. The aneurysm device can include a closure structure having a distal-facing aspect configured to at least partially occlude the aneurysm and a proximal-facing aspect configured to arch over lumina of an artery. The closure structure can include a plurality of struts forming support arms and anchoring arms. The device further includes a supplemental stabilizer connected to the closure structure and configured to reside in the artery and press outward against a luminal wall thereof. A barrier can span at least a portion of the distal-facing aspect of the closure structure and be configured to further occlude a neck of the aneurysm. The closure structure can be configured to restrict and/or divert flow to or from the aneurysm.Type: ApplicationFiled: August 17, 2022Publication date: December 8, 2022Applicant: PULSAR VASCULAR, INC.Inventors: Anthony BACHMAN, Chad ROUE, Marc JENSEN, Mike WALSH, Scott CAMERON, Michael GENDREAU, Robert M. ABRAMS
-
Patent number: 11457923Abstract: The present technology is directed generally to devices, systems, and methods for enclosing anatomical openings. In one example, an aneurysm device is endovascularly deliverable to a site proximate to an arterial aneurysm. The aneurysm device can include a closure structure having a distal-facing aspect configured to at least partially occlude the aneurysm and a proximal-facing aspect configured to arch over lumina of an artery. The closure structure can include a plurality of struts forming support arms and anchoring arms. The device further includes a supplemental stabilizer connected to the closure structure and configured to reside in the artery and press outward against a luminal wall thereof. A barrier can span at least a portion of the distal-facing aspect of the closure structure and be configured to further occlude a neck of the aneurysm. The closure structure can be configured to restrict and/or divert flow to or from the aneurysm.Type: GrantFiled: August 19, 2019Date of Patent: October 4, 2022Assignee: PULSAR VASCULAR, INC.Inventors: Anthony Bachman, Chad Roue, Marc Jensen, Mike Walsh, Scott Cameron, Michael Gendreau, Robert M. Abrams
-
Publication number: 20190365386Abstract: The present technology is directed generally to devices, systems, and methods for enclosing anatomical openings. In one example, an aneurysm device is endovascularly deliverable to a site proximate to an arterial aneurysm. The aneurysm device comprises a closure structure having a distal-facing aspect configured to at least partially occlude the aneurysm and a proximal-facing aspect configured to arch over lumina of an artery. The closure structure can include a plurality of struts forming support arms and anchoring arms. The device further includes a supplemental stabilizer connected to the closure structure and configured to reside in the artery and press outward against a luminal wall thereof. A barrier can span at least a portion of the distal-facing aspect of the closure structure and be configured to further occlude a neck of the aneurysm. The closure structure can be configured to restrict and/or divert flow to or from the aneurysm.Type: ApplicationFiled: August 19, 2019Publication date: December 5, 2019Applicant: PULSAR VASCULAR, INC.Inventors: Anthony BACHMAN, Chad ROUE, Marc JENSEN, Mike WALSH, Scott CAMERON, Michael GENDREAU, Robert M. ABRAMS
-
Patent number: 10426487Abstract: The present technology is directed generally to devices, systems, and methods for enclosing anatomical openings. In several embodiments, an aneurysm device is endovascularly deliverable to a site proximate to an arterial aneurysm. The aneurysm device includes a closure structure having a distal-facing aspect configured to at least partially occlude the aneurysm and a proximal-facing aspect configured to arch over lumina of an artery. The device further includes a supplemental stabilizer connected to the closure structure and configured to reside in the artery and press outward against a luminal wall thereof. In some embodiments, the device can also include a barrier spanning at least a portion of the distal-facing aspect of the closure structure and configured to further occlude a neck of the aneurysm. In further embodiments, the closure structure can be configured to restrict and/or divert flow to or from the aneurysm.Type: GrantFiled: April 25, 2017Date of Patent: October 1, 2019Assignee: Pulsar Vascular, Inc.Inventors: Anthony Bachman, Chad Roue, Marc Jensen, Mike Walsh, Scott Cameron, Michael Gendreau, Robert M. Abrams
-
Publication number: 20170224353Abstract: The present technology is directed generally to devices, systems, and methods for enclosing anatomical openings. In several embodiments, an aneurysm device is endovascularly deliverable to a site proximate to an arterial aneurysm. The aneurysm device includes a closure structure having a distal-facing aspect configured to at least partially occlude the aneurysm and a proximal-facing aspect configured to arch over lumina of an artery. The device further includes a supplemental stabilizer connected to the closure structure and configured to reside in the artery and press outward against a luminal wall thereof. In some embodiments, the device can also include a barrier spanning at least a portion of the distal-facing aspect of the closure structure and configured to further occlude a neck of the aneurysm. In further embodiments, the closure structure can be configured to restrict and/or divert flow to or from the aneurysm.Type: ApplicationFiled: April 25, 2017Publication date: August 10, 2017Applicant: Pulsar Vascular, Inc.Inventors: Anthony BACHMAN, Chad ROUE, Marc JENSEN, Mike WALSH, Scott CAMERON, Michael GENDREAU, Robert M. ABRAMS
-
Patent number: 9636117Abstract: The present technology is directed generally to devices, systems, and methods for enclosing anatomical openings. In several embodiments, an aneurysm device is endovascularly deliverable to a site proximate to an arterial aneurysm. The aneurysm device includes a closure structure having a distal-facing aspect configured to at least partially occlude the aneurysm and a proximal-facing aspect configured to arch over lumina of an artery. The device further includes a supplemental stabilizer connected to the closure structure and configured to reside in the artery and press outward against a luminal wall thereof. In some embodiments, the device can also include a barrier spanning at least a portion of the distal-facing aspect of the closure structure and configured to further occlude a neck of the aneurysm. In further embodiments, the closure structure can be configured to restrict and/or divert flow to or from the aneurysm.Type: GrantFiled: July 24, 2015Date of Patent: May 2, 2017Assignee: PULSAR VASCULAR, INC.Inventors: Anthony Bachman, Chad Roue, Marc Jensen, Mike Walsh, Scott Cameron, Michael Gendreau, Robert M. Abrams
-
Publication number: 20150327867Abstract: The present technology is directed generally to devices, systems, and methods for enclosing anatomical openings. In several embodiments, an aneurysm device is endovascularly deliverable to a site proximate to an arterial aneurysm. The aneurysm device comprises a closure structure having a distal-facing aspect configured to at least partially occlude the aneurysm and a proximal-facing aspect configured to arch over lumina of an artery. The device further includes a supplemental stabilizer connected to the closure structure and configured to reside in the artery and press outward against a luminal wall thereof. In some embodiments, the device can also include a barrier spanning at least a portion of the distal-facing aspect of the closure structure and configured to further occlude a neck of the aneurysm. In further embodiments, the closure structure can be configured to restrict and/or divert flow to or from the aneurysm.Type: ApplicationFiled: July 24, 2015Publication date: November 19, 2015Inventors: Anthony Bachman, Chad Roue, Marc Jensen, Mike Walsh, Scott Cameron, Michael Gendreau, Robert M. Abrams
-
Patent number: 9119625Abstract: The present technology is directed generally to devices, systems, and methods for enclosing anatomical openings. In several embodiments, an aneurysm device is endovascularly deliverable to a site proximate to an arterial aneurysm. The aneurysm device includes a closure structure having a distal-facing aspect configured to at least partially occlude the aneurysm and a proximal-facing aspect configured to arch over lumina of an artery. The device further includes a supplemental stabilizer connected to the closure structure and configured to reside in the artery and press outward against a luminal wall thereof. In some embodiments, the device can also include a barrier spanning at least a portion of the distal-facing aspect of the closure structure and configured to further occlude a neck of the aneurysm. In further embodiments, the closure structure can be configured to restrict and/or divert flow to or from the aneurysm.Type: GrantFiled: October 5, 2012Date of Patent: September 1, 2015Assignee: Pulsar Vascular, Inc.Inventors: Anthony Bachman, Chad Roue, Marc Jensen, Mike Walsh, Scott Cameron, Michael Gendreau, Robert M. Abrams
-
Patent number: 7994220Abstract: The present invention is directed to methods for providing long-term treatment of fibromyalgia syndrome (FMS) by administering a dual re-uptake inhibitor to a patient with FMS. More particularly, the present invention is directed to the long-term treatment of FMS by administering a norepinephrine-serotonin reuptake inhibitor (NSRI) to a patient with FMS.Type: GrantFiled: September 26, 2006Date of Patent: August 9, 2011Assignee: Cypress Bioscience, Inc.Inventors: Srinivas G. Rao, Michael Gendreau, Jay D. Kranzler
-
Publication number: 20110177531Abstract: The present invention provides methods of diagnosing and monitoring systemic lupus erythematosus by measuring cell-based complement activation products (CB-CAPS) in a subject's blood. In particular, the invention describes a diagnostic method employing the measurement of multiple complement activation products on the surfaces of red blood cells, white blood cells, and platelets (e.g., EC4d, BC4d, PC4d, and ECR1). A diagnostic algorithm utilizing the determined levels of CB-CAPS is also disclosed.Type: ApplicationFiled: October 15, 2010Publication date: July 21, 2011Applicant: EXAGEN DIAGNOSTICS, INC.Inventors: Thierry DERVIEUX, Michael GENDREAU, Rong ZABLOCKI
-
Publication number: 20100081719Abstract: Methods for treating fatigue associated with fibromyalgia by administering high-dose milnacipran to a patient suffering from such fatigue are provided. Also provided are methods for the long-term treatment of fatigue associated with FMS by administering milnacipran to a patient suffering from such fatigue.Type: ApplicationFiled: December 3, 2009Publication date: April 1, 2010Inventors: Srinivas G. Rao, R. Michael Gendreau, Jay D. Kranzler
-
Publication number: 20080293820Abstract: Methods for improving physical function in fibromyalgia syndrome by administering an NSRI such as milnacipran as disclosed.Type: ApplicationFiled: May 22, 2008Publication date: November 27, 2008Applicant: Cypress Bioscience, Inc.Inventors: Srinivas Rao, Michael Gendreau, Jay Kranzler
-
Publication number: 20070072946Abstract: The present invention is directed to methods for providing long-term treatment of fibromyalgia syndrome (FMS) by administering a dual re-uptake inhibitor to a patient with FMS. More particularly, the present invention is directed to the long-term treatment of FMS by administering a norepinephrine-serotonin reuptake inhibitor (NSRI) to a patient with FMS.Type: ApplicationFiled: September 26, 2006Publication date: March 29, 2007Applicant: Cypress Bioscience, Inc.Inventors: Srinivas Rao, Michael Gendreau, Jay Kranzler
-
Publication number: 20040106681Abstract: The present invention provides a method to treat neurological disorders. The method includes, e.g., administering higher daily dosages of anti-depressant. The higher daily dosages result in an improved efficacy of the drug, the maintenance of a positive patient toleration, the maintenance of a positive patient safety profile (e.g., dose limiting toxicity), a suitable peak plasma concentration (Cmax) of drug, and/or a once-a-day (QD) as opposed to twice-a-day (BID) administration. Applicant have discovered that increased daily dosages anti-depressant that would normally evoke adverse effects can be administered without the negative patient tolerability (i.e., adverse reactions) by escalating dosages over time. Such escalation dosages provide more efficacious amounts of anti-depressant than would otherwise be permitted. Similarly, higher levels of circulating drug are possible in patients by administering the compound in divided doses over the course of a day rather than once a day.Type: ApplicationFiled: October 3, 2003Publication date: June 3, 2004Applicant: Cypress Bioscience, Inc.Inventors: Srinivas G. Rao, Jay D. Kranzler, R. Michael Gendreau
-
Publication number: 20030176773Abstract: The present invention provides methods of assessing the level of a subjective symptom in a human subject. The methods involve randomly prompting the subject for his current level of the subjective symptom. Preferably, the methods are used while the subject is undergoing an intervention to try to decrease or ameliorate the level of the symptom.Type: ApplicationFiled: March 12, 2002Publication date: September 18, 2003Inventors: Roger Michael Gendreau, Srinivas Gandham Rao